Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 98


ABOUND.2L+: A randomized phase 2 study of nanoparticle albumin-bound paclitaxel with or without CC-486 as second-line treatment for advanced nonsquamous non-small cell lung cancer (NSCLC).

Morgensztern D, Cobo M, Ponce Aix S, Postmus PE, Lewanski CR, Bennouna J, Fischer JR, Juan-Vidal O, Stewart DJ, Fasola G, Ardizzoni A, Bhore R, Wolfsteiner M, Talbot DC, Jin Ong T, Govindan R, On Behalf Of The Abound L Investigators.

Cancer. 2018 Dec 15;124(24):4667-4675. doi: 10.1002/cncr.31779. Epub 2018 Nov 1.


Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer.

Basu B, Krebs MG, Sundar R, Wilson RH, Spicer J, Jones R, Brada M, Talbot DC, Steele N, Ingles Garces AH, Brugger W, Harrington EA, Evans J, Hall E, Tovey H, de Oliveira FM, Carreira S, Swales K, Ruddle R, Raynaud FI, Purchase B, Dawes JC, Parmar M, Turner AJ, Tunariu N, Banerjee S, de Bono JS, Banerji U.

Ann Oncol. 2018 Sep 1;29(9):1918-1925. doi: 10.1093/annonc/mdy245.


Reallocating sitting time to standing or stepping through isotemporal analysis: associations with markers of chronic low-grade inflammation.

Henson J, Edwardson CL, Bodicoat DH, Bakrania K, Davies MJ, Khunti K, Talbot DCS, Yates T.

J Sports Sci. 2018 Jul;36(14):1586-1593. doi: 10.1080/02640414.2017.1405709. Epub 2017 Nov 21.


Malignant pleural mesothelioma: an update on investigation, diagnosis and treatment.

Bibby AC, Tsim S, Kanellakis N, Ball H, Talbot DC, Blyth KG, Maskell NA, Psallidas I.

Eur Respir Rev. 2016 Dec;25(142):472-486. doi: 10.1183/16000617.0063-2016. Review.


Ocular Toxicity of Mitogen-Activated Protein Kinase Inhibitors.

Purbrick RMJ, Osunkunle OA, Talbot DC, Downes SM.

JAMA Oncol. 2017 Feb 1;3(2):275-277. doi: 10.1001/jamaoncol.2016.4213. No abstract available.


Targeted Next-Generation Sequencing of Plasma DNA from Cancer Patients: Factors Influencing Consistency with Tumour DNA and Prospective Investigation of Its Utility for Diagnosis.

Kaisaki PJ, Cutts A, Popitsch N, Camps C, Pentony MM, Wilson G, Page S, Kaur K, Vavoulis D, Henderson S, Gupta A, Middleton MR, Karydis I, Talbot DC, Schuh A, Taylor JC.

PLoS One. 2016 Sep 14;11(9):e0162809. doi: 10.1371/journal.pone.0162809. eCollection 2016.


Plant-rich mixed meals based on Palaeolithic diet principles have a dramatic impact on incretin, peptide YY and satiety response, but show little effect on glucose and insulin homeostasis: an acute-effects randomised study.

Bligh HF, Godsland IF, Frost G, Hunter KJ, Murray P, MacAulay K, Hyliands D, Talbot DC, Casey J, Mulder TP, Berry MJ.

Br J Nutr. 2015 Feb 28;113(4):574-84. doi: 10.1017/S0007114514004012. Epub 2015 Feb 9.


Climbazole increases expression of cornified envelope proteins in primary keratinocytes.

Pople JE, Moore AE, Talbot DC, Barrett KE, Jones DA, Lim FL.

Int J Cosmet Sci. 2014 Oct;36(5):419-26. doi: 10.1111/ics.12137. Epub 2014 Jul 25.


Reactive oxygen species production and mitochondrial dysfunction in white blood cells are not valid biomarkers of ageing in the very old.

Wiley L, Ashok D, Martin-Ruiz C, Talbot DC, Collerton J, Kingston A, Davies K, Chinnery PF, Catt M, Jagger C, Kirkwood TB, von Zglinicki T.

PLoS One. 2014 Mar 10;9(3):e91005. doi: 10.1371/journal.pone.0091005. eCollection 2014.


Capecitabine and streptozocin ± cisplatin in advanced gastroenteropancreatic neuroendocrine tumours.

Meyer T, Qian W, Caplin ME, Armstrong G, Lao-Sirieix SH, Hardy R, Valle JW, Talbot DC, Cunningham D, Reed N, Shaw A, Navalkissoor S, Luong TV, Corrie PG.

Eur J Cancer. 2014 Mar;50(5):902-11. doi: 10.1016/j.ejca.2013.12.011. Epub 2014 Jan 17.


Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052).

O'Brien ME, Gaafar RM, Popat S, Grossi F, Price A, Talbot DC, Cufer T, Ottensmeier C, Danson S, Pallis A, Hasan B, Van Meerbeeck JP, Baas P.

Eur J Cancer. 2013 Sep;49(13):2815-22. doi: 10.1016/j.ejca.2013.05.008. Epub 2013 Jun 20.


Quantitative analysis of survivin protein expression and its therapeutic depletion by an antisense oligonucleotide in human lung tumors.

Olsen AL, Davies JM, Medley L, Breen D, Talbot DC, McHugh PJ.

Mol Ther Nucleic Acids. 2012 Jun 19;1:e30. doi: 10.1038/mtna.2012.19.


The association between Lambert-Eaton myasthenic syndrome and small cell lung carcinoma.

Briggs SE, Gozzard P, Talbot DC.

Immunotargets Ther. 2013 May 21;2:31-7. doi: 10.2147/ITT.S31971. eCollection 2013. Review.


Effect of short-term reduced physical activity on cardiovascular risk factors in active lean and overweight middle-aged men.

Dixon NC, Hurst TL, Talbot DC, Tyrrell RM, Thompson D.

Metabolism. 2013 Mar;62(3):361-8. doi: 10.1016/j.metabol.2012.08.006. Epub 2012 Sep 17.


In reply: response to Marioni.

Church DN, Talbot DC.

Curr Oncol Rep. 2013 Feb;15(1):3. doi: 10.1007/s11912-012-0268-2. No abstract available.


Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer.

Ramalingam SS, Blackhall F, Krzakowski M, Barrios CH, Park K, Bover I, Seog Heo D, Rosell R, Talbot DC, Frank R, Letrent SP, Ruiz-Garcia A, Taylor I, Liang JQ, Campbell AK, O'Connell J, Boyer M.

J Clin Oncol. 2012 Sep 20;30(27):3337-44. doi: 10.1200/JCO.2011.40.9433. Epub 2012 Jul 2.


An investigation into the relationship between sleep-disordered breathing, the metabolic syndrome, cardiovascular risk profiles, and inflammation between South Asians and Caucasians residing in the United Kingdom.

Brady EM, Davies MJ, Hall AP, Talbot DC, Dick JL, Khunti K.

Metab Syndr Relat Disord. 2012 Apr;10(2):152-8. doi: 10.1089/met.2011.0073. Epub 2012 Jan 27.


Survivin in solid tumors: rationale for development of inhibitors.

Church DN, Talbot DC.

Curr Oncol Rep. 2012 Apr;14(2):120-8. doi: 10.1007/s11912-012-0215-2. Review.


Molecular Imaging and Pharmacokinetic Analysis of Carbon-11 Labeled Antisense Oligonucleotide LY2181308 in Cancer Patients.

Saleem A, Matthews JC, Ranson M, Callies S, André V, Lahn M, Dickinson C, Prenant C, Brown G, McMahon A, Talbot DC, Jones T, Price PM.

Theranostics. 2011;1:290-301. Epub 2011 Jun 1.


Continuous low-dose cyclophosphamide and methotrexate combined with celecoxib for patients with advanced cancer.

Khan OA, Blann AD, Payne MJ, Middleton MR, Protheroe AS, Talbot DC, Taylor M, Kirichek O, Han C, Patil M, Harris AL.

Br J Cancer. 2011 Jun 7;104(12):1822-7. doi: 10.1038/bjc.2011.154. Epub 2011 May 17. Erratum in: Br J Cancer. 2011 Oct 11;105(8):1252. Kirichek, O [added].


Reasons given by patients for participating, or not, in Phase 1 cancer trials.

Catt S, Langridge C, Fallowfield L, Talbot DC, Jenkins V.

Eur J Cancer. 2011 Jul;47(10):1490-7. doi: 10.1016/j.ejca.2011.02.020. Epub 2011 Mar 30.


Phase II study of single agent capecitabine in the treatment of metastatic non-pancreatic neuroendocrine tumours.

Medley L, Morel AN, Farrugia D, Reed N, Hayward N, Davies JM, Kirichek O, Thakker RV, Talbot DC.

Br J Cancer. 2011 Mar 29;104(7):1067-70. doi: 10.1038/bjc.2011.76. Epub 2011 Mar 8.


Association of long-term administration of the survivin mRNA-targeted antisense oligonucleotide LY2181308 with reversible kidney injury in a patient with metastatic melanoma.

Herrington WG, Talbot DC, Lahn MM, Brandt JT, Callies S, Nagle R, Winearls CG, Roberts IS.

Am J Kidney Dis. 2011 Feb;57(2):300-3. doi: 10.1053/j.ajkd.2010.09.024. Epub 2010 Dec 21. Erratum in: Am J Kidney Dis. 2011 May;57(5):804.


What oncologists believe they said and what patients believe they heard: an analysis of phase I trial discussions.

Jenkins V, Solis-Trapala I, Langridge C, Catt S, Talbot DC, Fallowfield LJ.

J Clin Oncol. 2011 Jan 1;29(1):61-8. doi: 10.1200/JCO.2010.30.0814. Epub 2010 Nov 22.


Tumor survivin is downregulated by the antisense oligonucleotide LY2181308: a proof-of-concept, first-in-human dose study.

Talbot DC, Ranson M, Davies J, Lahn M, Callies S, André V, Kadam S, Burgess M, Slapak C, Olsen AL, McHugh PJ, de Bono JS, Matthews J, Saleem A, Price P.

Clin Cancer Res. 2010 Dec 15;16(24):6150-8. doi: 10.1158/1078-0432.CCR-10-1932. Epub 2010 Nov 1. Erratum in: Clin Cancer Res. 2011 Apr 15;17(8):2602.


Active middle-aged men have lower fasting inflammatory markers but the postprandial inflammatory response is minimal and unaffected by physical activity status.

Dixon NC, Hurst TL, Talbot DC, Tyrrell RM, Thompson D.

J Appl Physiol (1985). 2009 Jul;107(1):63-8. doi: 10.1152/japplphysiol.91532.2008. Epub 2009 May 7.


Phase II study of vinflunine in malignant pleural mesothelioma.

Talbot DC, Margery J, Dabouis G, Dark G, Taylor H, Boussemart H, Cadic V, Pinel MC, Rivière A, Ollivier L, Ruffié P.

J Clin Oncol. 2007 Oct 20;25(30):4751-6.


Low-dose docosahexaenoic acid lowers diastolic blood pressure in middle-aged men and women.

Theobald HE, Goodall AH, Sattar N, Talbot DC, Chowienczyk PJ, Sanders TA.

J Nutr. 2007 Apr;137(4):973-8.


A randomized phase II pharmacokinetic and pharmacodynamic study of indisulam as second-line therapy in patients with advanced non-small cell lung cancer.

Talbot DC, von Pawel J, Cattell E, Yule SM, Johnston C, Zandvliet AS, Huitema AD, Norbury CJ, Ellis P, Bosquee L, Reck M.

Clin Cancer Res. 2007 Mar 15;13(6):1816-22.


Monoclonal antibody-based time-resolved fluorescence immunoassays for daidzein, genistein, and equol in blood and urine: application to the Isoheart intervention study.

Talbot DC, Ogborne RM, Dadd T, Adlercreutz H, Barnard G, Bugel S, Kohen F, Marlin S, Piron J, Cassidy A, Powell J.

Clin Chem. 2007 Apr;53(4):748-56. Epub 2007 Feb 22.


Isolation of a small molecule inhibitor of DNA base excision repair.

Madhusudan S, Smart F, Shrimpton P, Parsons JL, Gardiner L, Houlbrook S, Talbot DC, Hammonds T, Freemont PA, Sternberg MJ, Dianov GL, Hickson ID.

Nucleic Acids Res. 2005 Aug 19;33(15):4711-24. Print 2005.


Phase I study of MetXia-P450 gene therapy and oral cyclophosphamide for patients with advanced breast cancer or melanoma.

Braybrooke JP, Slade A, Deplanque G, Harrop R, Madhusudan S, Forster MD, Gibson R, Makris A, Talbot DC, Steiner J, White L, Kan O, Naylor S, Carroll MW, Kingsman SM, Harris AL.

Clin Cancer Res. 2005 Feb 15;11(4):1512-20.


A phase II study of etanercept (Enbrel), a tumor necrosis factor alpha inhibitor in patients with metastatic breast cancer.

Madhusudan S, Foster M, Muthuramalingam SR, Braybrooke JP, Wilner S, Kaur K, Han C, Hoare S, Balkwill F, Talbot DC, Ganesan TS, Harris AL.

Clin Cancer Res. 2004 Oct 1;10(19):6528-34.


Phase II trial of the antiangiogenic agent IM862 in metastatic renal cell carcinoma.

Deplanque G, Madhusudan S, Jones PH, Wellmann S, Christodoulos K, Talbot DC, Ganesan TS, Blann A, Harris AL.

Br J Cancer. 2004 Nov 1;91(9):1645-50.


Combination antiangiogenesis therapy with marimastat, captopril and fragmin in patients with advanced cancer.

Jones PH, Christodoulos K, Dobbs N, Thavasu P, Balkwill F, Blann AD, Caine GJ, Kumar S, Kakkar AJ, Gompertz N, Talbot DC, Ganesan TS, Harris AL.

Br J Cancer. 2004 Jul 5;91(1):30-6.


Pharmacokinetic study of cisplatin and infusional etoposide phosphate in advanced breast cancer with correlation of response to topoisomerase IIalpha expression.

Braybrooke JP, Levitt NC, Joel S, Davis T, Madhusudan S, Turley H, Wilner S, Harris AL, Talbot DC.

Clin Cancer Res. 2003 Oct 15;9(13):4682-8.


Comparison of prognostic factors in patients in phase I trials of cytotoxic drugs vs new noncytotoxic agents.

Han C, Braybrooke JP, Deplanque G, Taylor M, Mackintosh D, Kaur K, Samouri K, Ganesan TS, Harris AL, Talbot DC.

Br J Cancer. 2003 Oct 6;89(7):1166-71.


A phase 1 study of tazarotene in adults with advanced cancer.

Jones PH, Burnett RD, Fainaru I, Nadolny P, Walker P, Yu Z, Tang-Liu D, Ganesan TS, Talbot DC, Harris AL, Rustin GJ.

Br J Cancer. 2003 Sep 1;89(5):808-15.


Phase II study of exatecan mesylate (DX-8951f) as first line therapy for advanced non-small cell lung cancer.

Braybrooke JP, Ranson M, Manegold C, Mattson K, Thatcher N, Cheverton P, Sekiguchi M, Suzuki M, Oyama R, Talbot DC.

Lung Cancer. 2003 Aug;41(2):215-9.


Phase I and pharmacokinetic study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), using a weekly 30-minute intravenous infusion, in patients with advanced solid malignancies.

Braybrooke JP, Boven E, Bates NP, Ruijter R, Dobbs N, Cheverton PD, Pinedo HM, Talbot DC.

Ann Oncol. 2003 Jun;14(6):913-21.


Low-dose IFN-gamma induces tumor MHC expression in metastatic malignant melanoma.

Propper DJ, Chao D, Braybrooke JP, Bahl P, Thavasu P, Balkwill F, Turley H, Dobbs N, Gatter K, Talbot DC, Harris AL, Ganesan TS.

Clin Cancer Res. 2003 Jan;9(1):84-92.


Use of positron emission tomography in pharmacokinetic studies to investigate therapeutic advantage in a phase I study of 120-hour intravenous infusion XR5000.

Propper DJ, de Bono J, Saleem A, Ellard S, Flanagan E, Paul J, Ganesan TS, Talbot DC, Aboagye EO, Price P, Harris AL, Twelves C.

J Clin Oncol. 2003 Jan 15;21(2):203-10. Erratum in: J Clin Oncol. 2003 Aug 1;21(15):3006.


Randomised, phase II trial comparing oral capecitabine (Xeloda) with paclitaxel in patients with metastatic/advanced breast cancer pretreated with anthracyclines.

Talbot DC, Moiseyenko V, Van Belle S, O'Reilly SM, Alba Conejo E, Ackland S, Eisenberg P, Melnychuk D, Pienkowski T, Burger HU, Laws S, Osterwalder B.

Br J Cancer. 2002 May 6;86(9):1367-72.


Phase I and pharmacological study of the oral matrix metalloproteinase inhibitor, MMI270 (CGS27023A), in patients with advanced solid cancer.

Levitt NC, Eskens FA, O'Byrne KJ, Propper DJ, Denis LJ, Owen SJ, Choi L, Foekens JA, Wilner S, Wood JM, Nakajima M, Talbot DC, Steward WP, Harris AL, Verweij J.

Clin Cancer Res. 2001 Jul;7(7):1912-22.


Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C.

Propper DJ, McDonald AC, Man A, Thavasu P, Balkwill F, Braybrooke JP, Caponigro F, Graf P, Dutreix C, Blackie R, Kaye SB, Ganesan TS, Talbot DC, Harris AL, Twelves C.

J Clin Oncol. 2001 Mar 1;19(5):1485-92.


Duration of chemotherapy in advanced non-small-cell lung cancer: a randomized trial of three versus six courses of mitomycin, vinblastine, and cisplatin.

Smith IE, O'Brien ME, Talbot DC, Nicolson MC, Mansi JL, Hickish TF, Norton A, Ashley S.

J Clin Oncol. 2001 Mar 1;19(5):1336-43.


A phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis.

Braybrooke JP, O'Byrne KJ, Propper DJ, Blann A, Saunders M, Dobbs N, Han C, Woodhull J, Mitchell K, Crew J, Smith K, Stephens R, Ganesan TS, Talbot DC, Harris AL.

Clin Cancer Res. 2000 Dec;6(12):4697-704.


Reply to drs evans and robertson

Traill ZC, Gleeson EV, Talbot DC, Golding SJ.

Clin Radiol. 2000 Aug;55(8):653-4. No abstract available.


Evaluation of toremifene for reversal of multidrug resistance in renal cell cancer patients treated with vinblastine.

Braybrooke JP, Vallis KA, Houlbrook S, Rockett H, Ellmén J, Anttila M, Ganesan TS, Harris AL, Talbot DC.

Cancer Chemother Pharmacol. 2000;46(1):27-34.


Supplemental Content

Loading ...
Support Center